Clinical Trials Browser

Terminated × Lymphoma × pembrolizumab × Clear all

NCT03983668 2026-03-30

CMP-001 for Relapsed and Refractory Lymphoma

Phase 1/2 Terminated

14 enrolled 11 charts

Lymphoma

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Terminated

5 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03249792 2025-07-24

MK-2118-001

Phase 1 Terminated

140 enrolled 37 charts

Lymphoma

NCT04920383 2024-03-01

NEON-2

Phase 1 Terminated

Lymphoma

NCT04609579 2024-01-30

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1 Terminated

GastrointestinalGynecologicLymphoid

Bites and Stings, Lymphoma, Ovarian Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03815682 2022-12-06

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

Phase 1 Terminated

DermatologicLymphoid

Lymphoma, Melanoma